You are here: Industry Insights > Entyvio

News List

EC approves subcutaneous formulation of Entyvio as maintenance therapy in ulcerative colitis or Croh pharmaceutical-business-review
May 13, 2020
Takeda Pharmaceutical announced that the European Commission has granted a Marketing Authorization for the subcutaneous (SC) formulation of Entyvio (vedolizumab).
Royalty Pharma Acquires Royalties on Entyvio from Massachusetts General Hospital americanpharmaceuticalreview
March 09, 2020
Royalty Pharma has acquired Massachusetts General Hospital's (MGH) royalty interest in Entyvio (vedolizumab) for $94 million.
Physician View snap poll: Gastroenterologists assess the impact of Takeda's new head-to-head data for Entyvio in ulcerative colitis firstwordpharma
April 04, 2019
Takeda recently unveiled data showing Entyvio was superior to AbbVie's Humira at achieving clinical remission in moderate-to-severe ulcerative colitis patients at 52 weeks.
Takeda’s Entyvio achieves superior remission than Humira in ulcerative colitis pharmaceutical-technology
March 13, 2019
Takeda has announced results from Phase IIIb head-to-head study of two biologic therapies, Entyvio (vedolizumab) and adalimumab, the generic of AbbVie’s Humira, in which Entyvio achieved statistically significant clinical remission in patients with modera
Takeda’s Entyvio bests AbbVie’s Humira in ulcerative colitis trial pharmatimes
March 12, 2019
In the Phase III VARSITY trial, Entyvio (vedolizumab) was found to be superior to Humira (adalimumab) in achieving statistically significant clinical remission at week 52 in patients with moderately to severely active ulcerative colitis.
Takeda's Entyvio secures Japanese approval in ulcerative colitis pharmafile
July 06, 2018
As one of the most common forms of inflammatory bowel disease (IBD), ulcerative colitis affects over 220,000 people in Japan.
New analysis backs use of Takeda’s Entyvio pharmatimes
October 19, 2017
Takeda has presented data from a post-hoc analysis showing signs of early symptomatic improvement in patients with ulcerative colitis or Crohn’s disease taking Entyvio.